Current and future use of favipiravir in patients with COVID-19

Matveev, A. V.; Kiselev, Yu. Yu.; Сычев, Д. А.

doi:10.37489/2588-0519-2020-s4-106-114

Cited by 5 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among countries that implement favipiravir and HCQ in their treatment guidelines are China, Turkey, Spain, and Iran. T-705 is also used for the treatment of COVID-19 in China and Russia based on experimental and clinical observations performed mainly in China [56]. France, Italy, the Netherlands and South Korea also permit the use of CQ and CHQ for the treatment of certain hospitalized patients [57].…”

Section: Future Perspectives Of Favipiravir and Hydroxychloroquine An...mentioning

confidence: 99%

A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19

Pavlova¹,

Hristova²,

Uzunova³

et al. 2021

Res Rev Insights

View full text Add to dashboard Cite

The global COVID-19 pandemic, caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), spread rapidly across the globe. The lack of available therapies was an essential condition to repurpose available medicines for the treatment or prevention of that worrisome condition. It was our aim to summarize the available knowledge about the mechanism of action of the antirheumatic drugs chloroquine/hydroxychloroquine and the antiviral drug favipiravir. Further, the concomitant therapeutic potential of both drugs is discussed. The multiple mechanisms of action of CQ/HCQ as well as their immunomodulatory properties are still under investigation in COVID-19 treatment. The nucleoside analogue favipiravir is rapidly metabolized in host cells which disrupts viral synthesis and leads to mutagenesis. Clinical trials become available that provide evidence of the beneficial effect of concomitant use of both drugs in mild-COVID-19 patients. Simultaniously, side effects like QTc prolongation or teratogenicity pose risk to extensive community application. Future well designed, large randomized clinical trials are awaited to determine the role if any of those medications in COVID-19 therapy.

show abstract

Section: Future Perspectives Of Favipiravir and Hydroxychloroquine An...mentioning

confidence: 99%

A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19

Pavlova¹,

Hristova²,

Uzunova³

et al. 2021

Res Rev Insights

View full text Add to dashboard Cite

show abstract

“…На ранних этапах эпидемии и практически до конца 2021 г. из доступных в реальной клинической практике противовирусных средств в арсенале врачей имелись лишь ремдесивир и фавипиравир, которые были включены в протоколы терапии COVID-19 в различных странах мира [2, 12,14]. Необходимо отметить, что и ремдесивир, и фавипиравир являются препаратами с достаточно большим набором побочных эффектов, причем одним их главных среди них является гепатотоксичность, которая в ходе лечения может стать лимитирующим фактором для успешного завершения полноценного курса этиотропной терапии и вызвать неблагоприятные последствия, особенно у лиц с отягощенным преморбидным фоном, для которых характерно особенно тяжелое течение CОVID-19 [6,[12][13][14]. Максимально длительное удержание пациента на успешной схеме лечения и нивелирование побочных эффектов про-covid-19 тивовирусной терапии с использованием вспомогательных лекарственных средств может позволить сохранить эффективную схему этиотропного лечения, что крайне важно для пациентов с COVID-19.…”

unclassified

Metabolic support of antiviral therapy in patients with COVID-19

Shuldyakov

Lyapina

Smagina

et al. 2022

jour

View full text Add to dashboard Cite

Remaxol was evaluated as a means of hepatotropic support for patients with COVID-19 receiving antiviral therapy. Patients were observed in two groups of 30 people each and received intravenous infusions of Remaxol (400.0 ml) or “active placebo” (400.0 ml. 0.9% sodium chloride) for 10 days. In these groups of patients, an analysis was made of the dynamics of clinical parameters and laboratory tests that characterize the functionality of the liver. The results of the analysis made it possible to state that the use of the corrector of cellular and energy metabolism metabolism Remaxol as a hepatoprotector in complex therapy contributes to favorable clinical dynamics, stabilization of biochemical parameters of liver function and allows completing the course of etiotropic therapy in all patients.Good tolerability of the drug “Remaxol” and the absence of pronounced side eﬀects were noted. The course of Remaxol made it possible to carry out therapy with antiviral agents without dose adjustment and duration of treatment.

show abstract

On the question of antiviral therapy of a new coronavirus infection (COVID-19)

Skvortsov,

Skvortsova,

Gorbach

2023

Medsestra

View full text Add to dashboard Cite

Coronavirus infection, or COVID-19 (COronaVIrus Disease 2019), is a new epidemic infectious disease that poses a danger to the population due to its high contagiousness and the development of complications that are unfavorable for the patient’s life, such as ARDS, respiratory and multiple organ failure. The virus has spread worldwide since its detection in Wuhan, Hubei Province, China on December 12, 2019. The World Health Organization (WHO) has declared it a pandemic. Based on the Decree of the Government of the Russian Federation, the new coronavirus COVID-19 (SARS-COV-2) is included in the list of diseases dangerous to society, along with polio and plague. The world community, united by a common goal – to combat the pandemic, is taking measures to actively immunize the entire population through vaccination. However, despite the availability of many vaccines, the number of cases and deaths remains high. As of December 19, 2021, there were 274 644 270 confirmed cases of coronavirus infection in the world and 5 368 822 deaths. Based on the above data, it becomes obvious that the reasonable use of antiviral therapy drugs is necessary for a favorable outcome of the disease of each patient. The review examines the main antiviral drugs proposed by WHO for the treatment of new coronavirus infection (COVID-19). Studies with statistically significant data are selected, which make it possible to fully judge the effectiveness and make it possible to make an adequate decision on the prescription of these drugs. Based on the data obtained from in vitro studies and clinical trials, the prospect of using the above drugs in the treatment of a new coronavirus infection, their effectiveness in clinical practice, as well as the feasibility of using and possible combinations of prescribing these drugs, which can be used to treat and prevent a new coronavirus infection, are considered. The article discusses the effectiveness of the following drugs: remdesvir, interferon, lopinavir and ritonavir, riamilovir, ribavirin, umifenovir, darunavir and cobicistat, favipiravir, chloroquine and hydroxychloroquine, ivermectin and intravenous immunoglobulins.To achieve the goals and objectives of the TB service, a significant role belongs to the average medical staff, where there is a division of functional responsibilities.

show abstract

Current and future use of favipiravir in patients with COVID-19

Cited by 5 publications

References 41 publications

A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19

A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19

Metabolic support of antiviral therapy in patients with COVID-19

On the question of antiviral therapy of a new coronavirus infection (COVID-19)

Contact Info

Product

Resources

About